Cover Image
Market Research Report

Global Atopic Dermatitis Therapeutic Market - Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analytics, Current Market Size and Market Forecast 2018-2028

Published by GervanoRA Data Services LLP Product code 769588
Published Content info 233 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Atopic Dermatitis Therapeutic Market - Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analytics, Current Market Size and Market Forecast 2018-2028
Published: December 18, 2019 Content info: 233 Pages
Description

GervanoRA's Market Estimation report "Global Atopic Dermatitis Therapeutic Market - Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analytics, Current Market Size and Market Forecast 2018-2028" analyzed the current and upcoming opportunities in the Atopic Dermatitis area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Atopic Dermatitis industry. The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Atopic Dermatitis area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Atopic Dermatitis Drug Class, Route of Administration and Age Group. Report primarily focuses on the patent analysis of the key marketed and pipeline drugs to provide a brief understanding about the market opportunities in the Atopic Dermatitis competitive environment. We have also prognosticated the Atopic Dermatitis market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.

Our comprehensive analysis on the AD drug pipeline identified 133 drug candidates undergoing different stages of development- from Early R&D to Pre-registration stage. Among these, fifteen drug candidates are in the Phase 3 stage of development, a majority i.e. 46 candidates are in Phase 2 stage, twenty drug candidates are in Phase 1 stage of development and a total of 51 molecules are in non clinical stage of development. We have also identified fourteen drug molecules that are inactive with no drug updates from the year 2015 or have been discontinued. Among them four have been discontinued from further development for AD.

The report has covered more than 110 companies worldwide, involved in the development of new therapeutics for treatment of AD. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 15 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Estimated Pipeline Drug Approval Timelines
  • Current and Future Competitive Landscape
  • Key Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments
  • Pipeline Drug Descriptions along with Development milestones (Past and Future)
  • Atopic Dermatitis market in the 11 major markets along with the revenue and share from 2018 to 2028
  • Therapeutic market segmentation by drug class, route of administration and geography to better understand and study the individual market segment.
  • For each segment, the current market trends, growth factors, unmet needs and opportunities, along with market size 2017 and forecast 2018-2028
Table of Contents
Product Code: GERPHME014

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2 EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. MARKET SNAPSHOT, 2017-2028
  • 2.3. KEY EVENTS IN ATOPIC DERMATITIS COMPETITIVE SPACE
  • 2.4. KEY MAJOR FINDINGS
    • 2.4.1. DRIVERS
    • 2.4.2. RESTRAINTS
    • 2.4.3. UNMET NEEDS AND OPPORTUNITIES

3 DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION AND SYMPTOMS
  • 3.2. DISEASE CAUSE AND DIAGNOSIS
  • 3.3. TREATMENT ALGORITHMS AND GUIDELINES
  • 3.4. EPIDEMIOLOGY AND DISEASE BURDEN
  • 3.5. EPIDEMIOLOGY STUDIES
    • 3.5.1. GLOBAL AND HISTORICAL TRENDS
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4 MARKET DYNAMICS

  • 4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
  • 4.2. PRICING AND REIMBURSEMENT
  • 4.3. DEALS (MERGERS/ACQUISITIONS/ COLLABORATIONS)
    • 4.3.1 DEAL ANALYTICS BY DEAL TYPE
    • 4.3.2. DEAL ANALYTICS BY ANNUAL FREQUENCY
    • 4.3.3. DEAL ANALYTICS BY ACTIVE PLAYERS
  • 4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
  • 4.5. NEW DRUG APPROVAL (EX-US) SINCE 2010
  • 4.6. PATENT ANALYTICS (EXPIRIES AND GENERICIZATION)
    • 4.6.1. PATENT ANALYTICS OF APPROVED PRODUCTS
    • 4.6.2. PATENT ANALYTICS OF KEY PIPELINE PRODUCTS

5 PIPELINE ANALYTICS AND ESTIMATED APPROVAL TIMELINES

  • 5.1. PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
    • 5.1.1. PRE-REGISTRATION MOLECULES
    • 5.1.2. PHASE 3 MOLECULES
    • 5.1.3. PHASE 2 MOLECULES
    • 5.1.4. PHASE 1 MOLECULES
    • 5.1.5. PRECLINICAL MOLECULES
    • 5.1.6. EARLY R&D MOLECULES
    • 5.1.7. DISCONTINUED AND INACTIVE MOLECULES
  • 5.2. PIPELINE ANALYTICS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYTICS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYTICS BY MECHANISM OF ACTION
    • 5.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.6. ESTIMATED APPROVAL TIMELINE
    • 5.6.1. METHODOLOGY
    • 5.6.2. ESTIMATED APPROVAL TIMELINES US & EX-US

6 GLOBAL ATOPIC DERMATITIS MARKET BY DRUG CLASS

  • 6.1. INTRODUCTION
  • 6.2. CORTICOSTEROIDS
  • 6.3. EMOLLIENTS/MOISTURIZERS
  • 6.4. PDE-4 INHIBITOR
  • 6.5. CALCINEURIN INHIBITORS
  • 6.6. BIOLOGICS
  • 6.7. OTHERS

7 GLOBAL ATOPIC DERMATITIS THERAPEUTIC MARKET BY ROUTE OF ADMINISTRATION

  • 7.1. INTRODUCTION
  • 7.2. TOPICAL
  • 7.3. ORAL
  • 7.4. INJECTABLE

8 ATOPIC DERMATITIS MARKET BY METHOD OF DISPENSING

  • 8.1. INTRODUCTION
  • 8.2. PRESCRIPTION
  • 8.3. OTC

9 GLOBAL ATOPIC DERMATITIS THERAPEUTIC MARKET BY GEOGRAPHY

  • 9.1. INTRODUCTION
  • 9.2. US
  • 9.3. UK
  • 9.4. GERMANY
  • 9.5. FRANCE
  • 9.6. ITALY
  • 9.7. SPAIN
  • 9.8. CHINA
  • 9.9. JAPAN
  • 9.10. INDIA
  • 9.11. RUSSIA
  • 9.12. BRAZIL
  • 9.13. ROW

10 OPPORTUNITY ASSESSMENT AND COMPETITIVE BENCH-MARKING

  • 10.1. EXTERNAL DEPENDENCIES
  • 10.2. PIPELINE PORTFOLIO
  • 10.3. EXPECTED MARKET ENTRIES
  • 10.4. PATENTS AND EXCLUSIVITY
  • 10.5. MARKETING DYNAMICS AND PARTNERING
  • 10.6. 10.7. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES

COMPANY DEVELOPMENTS

11 CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 11.1. ESTABLISHED COMPANIES
    • 11.1.1. ESTABLISHED COMPANY PROFILES
      • 11.1.1.1. SANOFI
      • 11.1.1.2. PFIZER PHARMACEUTICALS
      • 11.1.1.3. REGENERON PHARMACEUTICALS INC
  • 11.2. EMERGING COMPANIES
    • 11.2.1. EMERGING COMPANY PROFILES
      • 11.2.1.1. UNION THERAPEUTICS A/S
      • 11.2.1.2. ANAPTYSBIO, INC
      • 11.2.1.3. ABEOME CORPORATION
      • 11.2.1.4. ASANA BIOSCIENCES, LLC
      • 11.2.1.5. SPHERIUM BIOMED S.L
      • 11.2.1.6. DS BIOPHARMA LIMITED
      • 11.2.1.7. RALEXAR THERAPEUTICS INC
      • 11.2.1.8. AKAAL PHARMA PTY LTD
      • 11.2.1.9. AOBIOME, LLC
      • 11.2.1.10. MENLO THERAPEUTICS INC
      • 11.2.1.11. BOTANIX PHARMACEUTICALS
      • 11.2.1.12. CARA THERAPEUTICS
      • 11.2.1.13. KYMAB LIMITED
      • 11.2.1.14. MATRISYS BIOSCIENCE
      • 11.2.1.15. QURIENT THERAPEUTICS

12. ABBREVIATIONS

LIST OF TABLES

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: ATOPIC DERMATITIS EPIDEMIOLOGY FORECAST OF US POPULATION (ADULTS) 2018-2025, MILLION
  • TABLE 03: TOP 10 DEALS RANKED BY THE DEAL AMOUNT
  • TABLE 04: MAJOR LICENSING DEALS IN ATOPIC DERMATITIS THERAPEUTIC AREA
  • TABLE 05: MAJOR ACQUISITIONS IN ATOPIC DERMATITIS THERAPEUTIC AREA
  • TABLE 06: MAJOR AGREEMENTS IN ATOPIC DERMATITIS THERAPEUTIC AREA
  • TABLE 07: MAJOR COLLABORATIONS IN ATOPIC DERMATITIS THERAPEUTIC AREA
  • TABLE 08: MAJOR FINANCING DEALS IN ATOPIC DERMATITIS THERAPEUTIC AREA
  • TABLE 09: ATOPIC DERMATITIS DEALS IN 2019
  • TABLE 10: US FDA APPROVED DRUGS SINCE 2010
  • TABLE 11: ATOPIC DERMATITIS APPROVED DRUGS (EX-US) SINCE 2010
  • TABLE 12: DUPIXENT US AND EU PATENTS OVERVIEW
  • TABLE 13: DUPIXENT PATENT EXPIRATIONS
  • TABLE 14: THE U.S PATENTS OF DS BIOPHARMA LIMITED
  • TABLE 15: THE U.S PATENTS OF AKAAL PHARMA PTY LTD.
  • TABLE 16: THE U.S PATENTS OF AOBIOME, LLC
  • TABLE 17: THE U.S PATENTS OF MENLO THERAPEUTICS INC.
  • TABLE 18: ATOPIC DERMATITIS PHASE 3 MOLECULES
  • TABLE 19: ATOPIC DERMATITIS PHASE 2 MOLECULES
  • TABLE 20: ATOPIC DERMATITIS PHASE 1 MOLECULES
  • TABLE 21: ATOPIC DERMATITIS PRECLINICAL MOLECULES
  • TABLE 22: ATOPIC DERMATITIS EARLY R&D STAGE MOLECULES
  • TABLE 23: ATOPIC DERMATITIS INACTIVE AND DISCONTINUED MOLECULES
  • TABLE 24: ATOPIC DERMATITIS PIPELINE ANALYTICS BY TOPICAL ROA
  • TABLE 25: ATOPIC DERMATITIS PIPELINE ANALYTICS BY ORAL ROA
  • TABLE 26: ATOPIC DERMATITIS PIPELINE ANALYTICS BY INJECTABLE ROA
  • TABLE 27: ATOPIC DERMATITIS PIPELINE ANALYTICS, IMMUNOMODULATORS
  • TABLE 28: ATOPIC DERMATITIS PIPELINE ANALYTICS, PDE4 INHIBITORS
  • TABLE 29: ATOPIC DERMATITIS PIPELINE ANALYTICS, ANTI-INFLAMMATORY
  • TABLE 30: ATOPIC DERMATITIS PIPELINE ANALYTICS, ANTI-MICROBIAL
  • TABLE 31: ATOPIC DERMATITIS PIPELINE ANALYTICS, JAK INHIBITORS
  • TABLE 32: ESTIMATED APPROVAL TIMELINES OF KEY ATOPIC DERMATITIS PIPELINE DRUGS
  • TABLE 33: GLOBAL AD MARKET BY DRUG CLASS, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 34: AVAILABLE TOPICAL AND SYSTEMIC CORTICOSTEROIDS
  • TABLE 35: GLOBAL CORTICOSTEROIDS MARKET FOR AD BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 36: GLOBAL EMOLLIENTS MARKET FOR AD BY COUNTRY,MARKET SIZE (2017),FORECAST (2018-2028)
  • TABLE 37: GLOBAL PDE4 INHIBITOR MARKET FOR AD BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 38: GLOBAL CALCINEURIN INHIBITORS MARKET FOR AD BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 39: GLOBAL BIOLOGICS MARKET FOR AD BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 40: GLOBAL OTHER DRUGS MARKET FOR AD BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 41: GLOBAL AD MARKET FOR ROA BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 42: GLOBAL AD MARKET FOR TOPICAL DRUGS BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 43: GLOBAL AD MARKET FOR ORAL DRUGS BY COUNTRY, MARKET SIZE (2017),FORECAST (2018-2028)
  • TABLE 44: GLOBAL AD MARKET FOR INJECTABLE DRUGS BY COUNTRY, MARKET SIZE (2017),FORECAST (2018-2028)
  • TABLE 45: GLOBAL AD MARKET FOR METHOD OF DISPENSING BY TYPE,MARKET SIZE (2017),FORECAST (2018-2028)
  • TABLE 46: GLOBAL AD MARKET FOR PRESCRIPTION DRUGS BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 47: GLOBAL AD MARKET FOR OTC DRUGS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 48: GLOBAL AD MARKET BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 49: US AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 50: US AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 51: US AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 52: UK AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 53: UK AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 54: UK AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 55: GERMANY AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 56: GERMANY AD MARKET FOR ROA BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 57: GERMANY AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 58: FRANCE AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 59: FRANCE AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 60: FRANCE AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 61: ITALY AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 62: ITALY AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 63: ITALY AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 64: SPAIN AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 65: SPAIN AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 66: SPAIN AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 67: CHINA AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 68: CHINA AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 69: CHINA AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 70: JAPAN AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 71: JAPAN AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 72: JAPAN AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 73: INDIA AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 74: INDIA AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 75: INDIA AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 76: RUSSIA AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 77: RUSSIA AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 78: RUSSIA AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 79: BRAZIL AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 80: BRAZIL AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 81: BRAZIL AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 82: ROW AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 83: ROW AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 84: ROW AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 85: RANKING OF TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES
  • TABLE 86: REVENUES GAINED THROUGH THE SALE OF MAJOR PRODUCTS IN MILLION $
  • TABLE 87: SANOFI'S OWNED PATENTS COVERING DUPIXENT
  • TABLE 88: SANOFI'S DEVELOPMENT PIPELINE UNDER NEURODEGENERATION
  • TABLE 89: SANOFI'S DEVELOPMENT PIPELINE UNDER INFLAMMATION AND IMMUNOLOGY
  • TABLE 90: SANOFI'S DEVELOPMENT PIPELINE UNDER ONCOLOGY
  • TABLE 91: SANOFI'S DEVELOPMENT PIPELINE UNDER RARE DISEASES
  • TABLE 92: SANOFI'S DEVELOPMENT PIPELINE UNDER RARE BLOOD DISORDERS
  • TABLE 93: SANOFI'S DEVELOPMENT PIPELINE UNDER VACCINES
  • TABLE 94: SANOFI'S RESEARCH AND DEVELOPMENT ACTIVITITES
  • TABLE 95: SANOFI'S RECENT DEVELOPMENTS
  • TABLE 96: SANOFI'S ANTICIPATED MILESTONES
  • TABLE 97: PFIZER TOP 5 PRODUCTS UNDER MAJOR PRODUCTS IN BIOPHARMA SEGEMENT
  • TABLE 98: PFIZER TOP 5 PRODUCTS UNDER MAJOR PRODUCTS IN UPJOHN SEGMENT
  • TABLE 99: CLINICAL PROGRAMS UNDER INFLAMMATION AND IMMUNOLOGY AREA
  • TABLE 99: CLINICAL PROGRAMS UNDER INTERNAL MEDICINES
  • TABLE 100: CLINICAL PROGRAMS UNDER ONCOLOGY THERAPY AREA
  • TABLE 101: CLINICAL PROGRAMS UNDER RARE DISEASES
  • TABLE 102: CLINICAL PROGRAMS UNDER VACCINES
  • TABLE 103: RESEARCH AND DEVELOPMENT ACTIVITIES OF PFIZER
  • TABLE 104: RECENT DEVELOPMENTS MADE BY PFIZER
  • TABLE 105: REGENERON'S MAJOR PRODUCTS IN THE U.S MARKET AREA FOR THE FIRST 9 MONTHS OF 2019
  • TABLE 106: REGENERON'S MAJOR PRODUCTS IN THE U.S AREA(FIRST 9 MONTHS, 2019) COLLABORATED WITH SANOFI
  • TABLE 107: PATENT INFORMATION WITH RESPECT TO DUPIXENT
  • TABLE 108: CLINICAL PROGRAMS UNDER IMMUNOLOGY AND INFLAMMATORY DISEASES
  • TABLE 109: CLINICAL PROGRAMS UNDER ONCOLOGY
  • TABLE 110: CLINICAL PROGRAMS UNDER CARDIOVASCULAR/METABOLIC DISEASES AND RARE DISEASES
  • TABLE 111: RESEARCH AND DEVELOPMENT ACTIVITIES OF REGENERON
  • TABLE 112: RECENT DEVELOPMENTS OF REGENERON
  • TABLE 113: UNION THERAPEUTICS PRODUCT PIPELINE
  • TABLE 114: UNION THERAPEUTICS RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 115: UNION THERAPEUTICS RECENT DEVELOPMENT ACTIVITIES
  • TABLE 116: UNION THERAPEUTICS PRESENTATIONS
  • TABLE 117: ANAPTYSBIO PRODUCT PIPELINE
  • TABLE 118: ANAPTYSBIO ANTICIPATED FUTURE MILESTONES
  • TABLE 119: ANAPTYSBIO RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 120: ANAPTYSBIO PRESENTATIONS AND CONFERENCES
  • TABLE 121: ABEOME PRODUCT PIPELINE
  • TABLE 122: ABEOME RECENT DEVELOPMENTS
  • TABLE 123: ABEOME PRESENTATION
  • TABLE 124: ASANA BIOSCIENCES PRODUCT PIPELINE
  • TABLE 125: ASANA BIOSCIENCES RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 126: ASANA BIOSCIENCES ACHIEVED MILESTONES
  • TABLE 127: ASANA BIOSCIENCES PUBLICATIONS
  • TABLE 128: ASANA BIOSCIENCES PRESENTATIONS AND CONFERENCES
  • TABLE 129: SPHERIUM BIOMED PRODUCT PIPELINE
  • TABLE 130: SPHERIUM BIOMED RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 131: SPHERIUM BIOMED RECENT DEVELOPMENT ACTIVITIES
  • TABLE 132: SPHERIUM BIOMED PRESENTATIONS
  • TABLE 133: DS BIOPHARMA PRODUCT PIPELINE
  • TABLE 134: DS BIOPHARMA U.S PATENTS
  • TABLE 135: DS BIOPHARMA RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 136: DS BIOPHARMA RECENT DEVELOPMENT ACTIVITIES
  • TABLE 137: DS BIOPHARMA COLLABORATIONS
  • TABLE 138: DS BIOPHARMA PRESENTATIONS/EVENTS AND CONFERENCES
  • TABLE 139: RALEXAR THERAPEUTICS U.S PATENTS
  • TABLE 140: RALEXAR THERAPEUTICS RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 141: RALEXAR THERAPEUTICS MILESTONE ACHIEVEMENTS
  • TABLE 142: AKAAL PHARMA PRODUCT PIPELINE
  • TABLE 143: AKAAL PHARMA U.S PATENTS
  • TABLE 144: AKAAL PHARMA RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 145: AKAAL PHARMA RECENT DEVELOPMENT ACTIVITIES
  • TABLE 146: AKAAL PHARMA PRESENTATION
  • TABLE 147: AOBIOME PRODUCT PIPELINE
  • TABLE 148: AOBIOME U.S PATENTS
  • TABLE 149: AOBIOME RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 150: AOBIOME RECENT DEVELOPMENT ACTIVITIES
  • TABLE 151: AOBIOME PRESENTATION
  • TABLE 152: MENLO THERAPEUTICS PRODUCT PIPELINE
  • TABLE 153: MENLO THERAPEUTICS U.S PATENTS
  • TABLE 154: MENLO THERAPEUTICS RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 155: MENLO THERAPEUTICS RECENT DEVELOPMENT ACTIVITIES
  • TABLE 156: MENLO THERAPEUTICS PRESENTATIONS
  • TABLE 157: MENLO THERAPEUTICS MILESTONE ACHIEVED
  • TABLE 158: BOTANIX PRODUCT PIPELINE
  • TABLE 159: BOTANIX RESEARCH AND DEVELOPMENTS
  • TABLE 160: BOTANIX RECENT DEVELOPMENTS
  • TABLE 161: BOTANIX PRESENTATIONS
  • TABLE 162: CARA THERAPEUTICS PRODUCT PIPELINE
  • TABLE 163: CARA THERAPEUTICS RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 164: CARA THERAPEUTICS RECENT DEVELOPMENT ACTIVITIES
  • TABLE 165: CARA THERAPEUTICS PRESENTATIONS
  • TABLE 166: KYMAB PRODUCT PIPELINE
  • TABLE 167: KYMAB RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 168: KYMAB RECENT DEVELOPMENT ACTIVITIES
  • TABLE 169: KYMAB PRESENTATIONS
  • TABLE 170: KYMAB CONFERENCES
  • TABLE 171: KYMAB PUBLICATIONS
  • TABLE 172: MATRISYS PRODUCT PIPELINE
  • TABLE 173: MATRISYS PUBLICATIONS
  • TABLE 174: QURIENT PRODUCT PIPELINE
  • TABLE 175: QURIENT RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 176: QURIENT RECENT DEVELOPMENT ACTIVITIES
  • TABLE 177: QURIENT PUBLICATIONS

LIST OF FIGURES

  • FIGURE 01: GLOBAL ATOPIC DERMATITIS MARKET BY GEOGRAPHY 2017 V/S 2028
  • FIGURE 02: GLOBAL ATOPIC DERMATITIS MARKET 2017-2028: MARKET SNAPSHOT
  • FIGURE 03: ATOPIC DERMATITIS MARKET BY METHOD OF DISPENSING, 2017
  • FIGURE 04: ATOPIC DERMATITIS MARKET BY ROA, 2017
  • FIGURE 05: KEY EVENTS IN ATOPIC DERMATITIS AREA
  • FIGURE 06: ATOPIC DERMATITIS EPIDEMIOLOGY FORECAST OF US POPULATION (ADULTS), IN MILLION
  • FIGURE 07: ATOPIC DERMATITIS DEALS, GEOGRAPHY SPLIT-UP
  • FIGURE 08: ATOPIC DERMATITIS THERAPEUTIC AREA DEALS OVERVIEW
  • FIGURE 09: ATOPIC DERMATITIS DEALS ANNUAL FREQUENCY, 2011-2019
  • FIGURE 10: ATOPIC DERMATITIS DRUG PIPELINE, HSD SPLIT
  • FIGURE 11: ATOPIC DERMATITIS DRUG PIPELINE SPLIT BY GEOGRAPHY
  • FIGURE 12: ATOPIC DERMATITIS DRUG PIPELINE SPLIT, MAJOR APPROVAL MARKETS
  • FIGURE 13: ATOPIC DERMATITIS DRUG PIPELINE SPLIT BY ROA
  • FIGURE 14: TOPICALS BY HSD SPLIT-UP
  • FIGURE 15: ORALS BY HSD SPLIT-UP
  • FIGURE 16: PIPELINE ANALYTICS BY INJECTABLES, SPLIT BY TECHNIQUE USED
  • FIGURE 17: INJECTABLES BY HSD SPLIT-UP
  • FIGURE 18: ATOPIC DERMATITIS DRUG CLASSES SCENARIO
  • FIGURE 19: ANTI-INFLAMMATORY DRUGS SPLIT BY HSD
  • FIGURE 20: JAK INHIBITORS SPLIT BY HSD
  • FIGURE 21: CORTICOSTERIODS HOLD MAXIMUM SHARE IN THE ATOPIC DERMATITIS MARKET, 2018
  • FIGURE 22: GLOBAL CORTICOSTEROIDS MARKET, 2018 V/S 2028
  • FIGURE 23: GLOBAL EMOLLIENTS/MOISTURIZERS MARKET, 2018 V/S 2028
  • FIGURE 24: GLOBAL PDE4 INHIBITORS MARKET, 2018 V/S 2028
  • FIGURE 25: GLOBAL CALCINEURIN INHIBITORS MARKET, 2018 V/S 2028
  • FIGURE 26: GLOBAL BIOLOGICS MARKET, 2018 V/S 2028
  • FIGURE 27: OTHER DRUGS MARKET, 2018 V/S 2028
  • FIGURE 28: TOPICAL ROA IS EXPECTED TO HOLD MAXIMUM SHARE IN THE AD MARKET, 2018
  • FIGURE 29: GLOBAL ATOPIC DERMATITIS ROA SCENARIO, 2017
  • FIGURE 30: GLOBAL TOPICAL DRUGS MARKET, 2018 V/S 2028
  • FIGURE 31: GLOBAL ORALS DRUGS MARKET, 2018 V/S 2028
  • FIGURE 32: GLOBAL INJECTABLES DRUGS MARKET, 2018 V/S 2028
  • FIGURE 33: PRESCRIPTION SEGMENT IS EXPECTED TO HOLD MAXIMUM SHARE IN THE AD MARKET, 2018
  • FIGURE 34: GLOBAL ATOPIC DERMATITIS MARKET BY METHOD OF DISPENSING, 2017
  • FIGURE 35: GLOBAL PRESCRIPTION MARKET, 2018 V/S 2028
  • FIGURE 36: GLOBAL OTC MARKET, 2018 V/S 2028
  • FIGURE 37: GLOBAL ATOPIC DERMATITIS MARKET SPLIT BY 11 MM, 2018 V/S 2028
  • FIGURE 38: GLOBAL ATOPIC DERMATITIS MARKET SPLIT BY 11 MM, 2018
  • FIGURE 39: US DRUG CLASS MARKET SPLIT, 2018
  • FIGURE 40: US ROA MARKET SPLIT, 2018
  • FIGURE 41: US MARKET FOR METHOD OF DISPENSING, 2018
  • FIGURE 42: UK DRUG CLASS MARKET SPLIT, 2018
  • FIGURE 43: UK ROA MARKET SPLIT, 2018 V/S 2028
  • FIGURE 44: UK MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028
  • FIGURE 45: GERMANY DRUG CLASS MARKET, 2018 V/S 2028
  • FIGURE 46: GERMANY ROA MARKET SPLIT, 2028
  • FIGURE 47: GERMANY MARKET FOR METHOD OF DISPENSING, 2028
  • FIGURE 48: FRANCE DRUG CLASS MARKET SPLIT, 2018
  • FIGURE 49: FRANCE ROA MARKET SPLIT, 2018 V/S 2028
  • FIGURE 50: FRANCE MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028
  • FIGURE 51: ITALY DRUG CLASS MARKET, 2018 V/S 2028
  • FIGURE 52: ITALY ROA MARKET SPLIT, 2018
  • FIGURE 53: ITALY MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028
  • FIGURE 54: SPAIN DRUG CLASS MARKET SPLIT, 2018
  • FIGURE 55: SPAIN ROA MARKET SPLIT, 2018 V/S 2028
  • FIGURE 56: SPAIN MARKET FOR METHOD OF DISPENSING, 2018
  • FIGURE 57: CHINA DRUG CLASS MARKET SPLIT, 2018 V/S 2028
  • FIGURE 58: CHINA ROA MARKET SPLIT, 2028
  • FIGURE 59: CHINA MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028
  • FIGURE 60: JAPAN DRUG CLASS MARKET SPLIT, 2018
  • FIGURE 61: JAPAN ROA MARKET SPLIT, 2018 V/S 2028
  • FIGURE 62: JAPAN MARKET FOR METHOD OF DISPENSING, 2028
  • FIGURE 63: INDIA DRUG CLASS MARKET SPLIT, 2018 V/S 2028
  • FIGURE 64: INDIA ROA MARKET SPLIT, 2018 V/S 2028
  • FIGURE 65: INDIA MARKET FOR METHOD OF DISPENSING, 2028 V/S 2028
  • FIGURE 66: RUSSIA DRUG CLASS MARKET SPLIT, 2028
  • FIGURE 67: RUSSIA ROA MARKET SPLIT, 2028
  • FIGURE 68: RUSSIA MARKET FOR METHOD OF DISPENSING, 2028
  • FIGURE 69: BRAZIL DRUG CLASS MARKET SPLIT, 2018 V/S 2028
  • FIGURE 70: BRAZIL ROA MARKET SPLIT, 2018 V/S 2028
  • FIGURE 71: BRAZIL MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028
  • FIGURE 72: COMPARISON OF TOP FOUR COMPANIES BASED ON R&D INVESTMENTS IN MILLION $
  • FIGURE 73: PIPELINE PORTFOLIO WITH NUMBER OF MOLECULES
  • FIGURE 74: EXPECTED MARKET ENTRY IN THE U.S IRRESPECTIVE OF ATOPIC DERMATITIS MARKET
  • FIGURE 75: EXPECTED MARKET ENTRY IN THE U.S WITH RESPECT TO ATOPIC DERMATITIS MARKET
  • FIGURE 76: PATENT PORTFOLIO COMPARISON OF TOP 10 EMERGING COMPANIES
  • FIGURE 77: TIME LINE OF PATENT EXPIRIES IRRESPECTIVE OF ATOPIC DERMATITIS MARKET
  • FIGURE 78: TIME LINE OF PATENT EXPIRIES WITH RESPECT TO ATOPIC DERMATITIS
  • FIGURE 79: RANKING TOP 10 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES
  • FIGURE 80: COMPARISON PIE CHARTS FOR INCOME GAINED THROUGH SALES IN 2018 AND 2019
  • FIGURE 81: FINANCIAL INFORMATION OF PFIZER FOR 2016, 2017 AND 2018
  • FIGURE 82: REVENUE BREAKDOWN BETWEEN PFIZER'S SEGMENTS FOR THE FIRST NINE MONTHS ENDED IN 2019
  • FIGURE 83: FINANCIAL INFORMATION OF REGENERON FOR 2016, 2017 AND 2018
  • FIGURE 84: TOTAL REVENUE BREAKDOWN FOR THE FIRST NINE MONTHS OF 2019
  • FIGURE 85: NET LOSS FOR THE YEAR ENDED DECEMBER 31, 2017-18 (THOUSAND DOLLAR)
  • FIGURE 86: RESEARCH AND DEVELOPMENT EXPENSES FOR THE YEAR ENDED DECEMBER 31, 2017-18
  • FIGURE 87: NET LOSS FOR THE YEAR ENDED DECEMBER 31, 2018, 2017, 2016
Back to Top